Bostwick Laboratories is proud to offer ProstaVysion, a prognostic genetic panel for prostate cancer. A tissue-based panel, this test examines two major mechanisms of prostate carcinogenesis: ERG gene fusion/translocation and the loss of the PTEN tumor suppressor gene. By examining these two markers, ProstaVysion is able to provide a molecular analysis of prostate cancer aggressiveness and long-term patient prognosis. The ProstaVysion Score summarizes patient results with information present in published medical literature for a projected outcome of prostate cancer. These results are beneficial to physicians for guiding patient treatment decisions.


  • ERG gene fusions are found in 40% of primary prostate cancers [Carver 2009]
  • Associated with a more aggressive phenotype
  • Correlates with cancer stage, Gleason score, grade and cancer-specific survival rates [Yoshimoto 2009]


  • Key tumor suppressor gene in prostate cancer
  • Deletion of PTEN occurs in 20-40% of localized prostate cancers and up to 60% of metastases [Han 2009]

Both of these ProstaVysion panel markers provide useful, actionable and cost-effective prognostic information. ProstaVysion is available exclusively from Bostwick Laboratories, your partner in premium urological services.



1. Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA. “TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.” Oncogene. 2007 Jul 5;26(31):4596-9. Epub 2007 Jan 22.

2. Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, Linetzky KA, Palanisamy N, Zhou M, Chinnaiyan AM, Shah RB. “Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.” Mod Pathol. 2009 Sep;22(9):1176-85. Epub 2009 May 22.

3. Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB. “Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.” Mod Pathol. 2009 Aug;22(8):1083-93. Epub 2009 May 1.

4. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, Hicks JL, Meeker AK, Bieberich CJ, De Marzo AM, Epstein JI, Netto GJ. “ERG gene rearrangements are common in prostatic small cell carcinomas.” Mod Pathol. 2011 Feb 18.

5. Park, Kyung, Tomlins, Scott A, Mudaliar, Kumaran M, Chiu, Ya-Lin, Esgueva, Raquel, Mehra, Rohit, et. al. “Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer. Neoplasia.” 2010 July; 12(7): 590–598.

6. Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, Cox ME, Huntsman DG. “Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.” J Clin Pathol. 2007 Nov;60(11):1238-43. Epub 2007 Jan 26.

7. Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, Zielenska M, Soares FA, Squire JA. “Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.” Mod Pathol. 2008 Dec;21(12):1451-60. Epub 2008 May 23.


1. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Simons JW, Kitabayashi N, MacDonald TY, Kantoff PW, Chin L, Gabriel SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G, Rubin MA, Garraway LA. “The genomic complexity of primary human prostate cancer.” Nature. 2011 Feb 10;470(7333):214-20.

2. Bismar TA, Yoshimoto M, Vollmer RT, Duan Q, Firszt M, Corcos J, Squire JA. “PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.” BJU Int. 2011 Feb;107(3):477-85. doi: 10.1111/j.1464-410X.2010.09470.x.

3. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP. “Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.” Nat Genet. 2009 May;41(5):619-24. Epub 2009 Apr 26.

4. Liu S, Yoshimoto M, Trpkov K, Duan Q, Firszt M, Corcos J, Squire JA, Bismar TA. “Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone.” Cancer Biol Ther. 2011 Mar 15;11(6).

5. McCall P, Witton CJ, Grimsley S, Nielsen KV, Edwards J. “Is PTEN loss associated with clinical outcome measures in human prostate cancer?” Br J Cancer. 2008;99:1296–301.

6. Rubin MA, Gerstein A, Reid K, Bostwick DG, Cheng L, Parsons R, Papadopoulos N. “10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer.” Hum Pathol. 2000 Apr;31(4):504-8.